Journal Club Mallory McClester, PGY-4 August 16, 2013.

Slides:



Advertisements
Similar presentations
Analysis of the ADVANCE Trial Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 28, 2008.
Advertisements

Valsartan Antihypertensive Long-Term Use Evaluation Results
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Treatment of Hypertension in Patients over the age of 80 Debra Bynum, MD Associate Professor Division of Geriatric Medicine.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Flying Blind Without Instruments Treating Hypertension in the Elderly Will Bynum, MD Attending Faculty, NCC Family Medicine Residency Fort Belvoir, VA.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Hypertension and The Older Patient
Hypertension in the Elderly
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
Hypertension By Dr. Nagwa Eid Saad Prof. Of Internal Medicine & Family Medicine In Cairo University.
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Randomized, double-blind, multicenter, controlled trial.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Daily Dilemmas in Hypertension Management. Objectives Review the impact of hypertension on society Review the impact of hypertension on society Review.
Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
Peter Emery, MD Specialist in Clinical Hypertension InterMed Portland, ME.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Utilization Of Lipid-lowering Therapy In Hypertensive Patients In The United States Simon S.K. Tang, MPH* Sean Candrilli, MS** Lizheng Shi, PhD* *Department.
CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment.
Slide 1 Downloaded from Population Impact of Losartan Use on Stroke in the European Union (EU)
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Are the European Practice Guidelines for the Management of Arterial Hypertension (2007) adapted to the old and the frail? Anette Hylen
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/AHA 2011 Expert Consensus Document on Hypertension.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):
Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.
Management of Hypertension according to JNC 7
Nephrology Journal Club The SPRINT Trial Parker Gregg
The SPRINT Research Group
Copyright © 2015 American Medical Association. All rights reserved.
Blood Pressure and Age in Controlling Hypertension
Copyright © 2005 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
The Anglo Scandinavian Cardiac Outcomes Trial
Systolic Blood Pressure Intervention Trial (SPRINT)
Progress and Promise in RAAS Blockade
The Hypertension in the Very Elderly Trial (HYVET)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Diabetes Journal Club March 17, 2011
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Beth Wallace, BSN, RN-BC, FNP-S Fairfield University Summer 2010
Managing Blood Pressure
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.
Presentation transcript:

Journal Club Mallory McClester, PGY-4 August 16, 2013

Objectives  Review the article contents  Discussion of article critically  Feedback from the group  Final conclusions

Background  More than 50% of all adults >65 have hypertension.  Likelihood of developing htn during the average lifespan is >90%.  Hypertension, antihypertensive drugs, and fall injury form a complicated triad.

Background  Hypothesis: Initiating antihypertensive agents in the elderly has been associated with an increased risk of falls, and therefore increased risk of hip fracture.

Methods  Population based, self-controlled case series  Prescription Drug Database used to identify all Ontario residents aged 66+, initiating anti- hypertensive  All patients with other conditions for which an anti-hypertensive drug may be used were excluded

Methods  Cases: First occurrence of hip fx from 4/1/2000-3/31/2009  Linked to: Cohort of newly treated hypertensive elderly patients  To clarify, first patients over the age of 66 starting an antihypertensive were identified. From that, cases of hip fractures were studied specifically.

Methods  High risk period  45 days immediately following antihypertensive initiation, observe closely for orthostatic hypotension  Control period (low risk, unexposed)  3 consecutive 45 day periods in preexposure and postexposure  Total observation period was 450 days

Date of download: 8/14/2013 Copyright © 2012 American Medical Association. All rights reserved. From: The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly Arch Intern Med. 2012;172(22): doi: /2013.jamainternmed.469 Figure 1. Antihypertensive drug use and hip fracture risk: self-controlled case series design. Time division for each patient is included to assess incidence of first acute hip fracture in relation to antihypertensive prescription. All patients in the analysis had at least 1 prescription for an antihypertensive drug and a single incident hip fracture. Figure Legend :

Results  301,591 newly treated Ontario hypertensive elderly pts identified  Mean age (SD): 81 (7.3)  Gender: Females (80.7%)

Results  Hypertensive Elderly patients with hip fx:  Most exposed to ACE inhibitors (30.1%)  Least exposed to ARBs (4.4%)  This study shows that patients starting treatment had a 43% increased risk of hip fracture during the first 45 days of treatment.

Date of download: 8/14/2013 Copyright © 2012 American Medical Association. All rights reserved. From: The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly Arch Intern Med. 2012;172(22): doi: /2013.jamainternmed.469 Figure Legend :

Results  Incident Rate Ratio consistent among the 5 different classes of antihypertensive drugs  Only ACE-I and Beta-blockers were statistically significant

Date of download: 8/14/2013 Copyright © 2012 American Medical Association. All rights reserved. From: The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly Arch Intern Med. 2012;172(22): doi: /2013.jamainternmed.469 Figure 2. Forest plot of antihypertensive drugs and hip fracture risk using incidence rate ratios with 95% CIs. Each data point and 95% CI (error bars) represent results from the conditional Poisson regression analysis. The line at 1.0 represents no association; estimates to the right of the line represent an increased risk of hip fracture. ACE indicates angiotensin II converting–enzyme; ARB, angiotensin II receptor antagonist/blocker; BB, β-adrenergic blocker; and CCB, calcium channel blocker. Figure Legend :

Date of download: 8/14/2013 Copyright © 2012 American Medical Association. All rights reserved. From: The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly Arch Intern Med. 2012;172(22): doi: /2013.jamainternmed.469 Figure Legend :

Date of download: 8/14/2013 Copyright © 2012 American Medical Association. All rights reserved. From: The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly Arch Intern Med. 2012;172(22): doi: /2013.jamainternmed.469 Figure 1. Antihypertensive drug use and hip fracture risk: self-controlled case series design. Time division for each patient is included to assess incidence of first acute hip fracture in relation to antihypertensive prescription. All patients in the analysis had at least 1 prescription for an antihypertensive drug and a single incident hip fracture. Figure Legend :

Discussion  Demonstrates immediate increased risk of hip fracture on initiation of antihypertensive tx in community dwelling hypertensive elderly patients.  Main mechanism supported is orthostatic hypotension leading to falls.

Discussion  Thiazide diuretics:  No statistical difference  ACE inhibitors  First dose hypotension? related to venodilation  Beta blockers  Likely Less effective in controlling hypertension in elderly

Discussion  Identified Strengths of Study  Large population based study (301,591)  10 year period  Self controlled case series allowed for study of this association  Selection bias avoided (only used cases)  Removed fixed covariates  Identified Limitations  Patients may have been exposed to antihypertensives before age 65  Drug Samples?  No investigation of specific subclasses of medications

Critically Speaking  Why is this relevant?  Using these medications is beneficial long term even if short term risk may be increased

Relevance: How Common is Systolic Hypertension?  Prevalence of HTN increases with age  67% over age 60 and ¾ of those over the age of 70 have HTN (National Health and Nutrition Examination Survey: NHANES)  SH accounts for 75% of HTN in those over 65  Lifetime Risk Statistic:  Normotensive 65 year old adult who lives to age 85: 90% lifetime probability of developing stage 1 HTN ( /90- 99) and 40% risk of stage 2 HTN (>160/100)

Meta-analysis  8 trials, over 15,000 patients with SH  Median follow up 3.8 years  Treatment decreased mortality by 13%, stroke by 30%

NNT for 5 years to prevent one major CV event….

HYVET: Hypertension in the Very Elderly Trial  RCT of nearly 4000 patients from Europe, China, Australia, Tunisia  Age over 80  SBP > 160  Indapamide vs placebo  ACE inhibitor (perindopril) or placebo added as second agent when needed  Primary endpoint: stroke

HYVET…  Mean age : 83  Mean standing BP: 173/90  12% had hx of CV disease  1.8 year follow up  Treatment group: 15/6 lower BP

HYVET: results EndpointTreatment (rate per 1000 patient-year/# events) Placebo Stroke12.4 (51)17.7 (69) Death from stroke6.5 (27)10.7 (42) Mortality47.2 (196)59.6 (235) Death from CV cause23.9 (99)30.7 (121) Any MI2.2 (9)3.1 (12) p=.45 Any heart failure5.3 (22)14.8 (57) Any CV event33.7 (138)50.6 (193) Any CV event:Death from CV cause, stroke, MI, CHF

HYVET results…  30% decrease in rate of fatal or nonfatal stroke  39% decrease in rate of death from stroke  21 % decrease in all cause mortality  23% decrease in CV death  64% decrease in heart failure  Fewer adverse events in treatment group  7.9% in treatment group vs 8.8% in placebo group had orthostatic hypotension

HYVET: Take Home points  Overall number of events small (healthy population of elderly)  Stroke: ARR of almost 1% (NNT near 100 over 2 years to prevent one stroke)  Older patients more likely to die from stroke  All cause mortality (secondary outcome): ARR 1.2 % (NNT about 80)

Discussion  So looking more closely at the study data and applying this information:  Roughly 300,000 patients  1436 have hip fractures  143 occurred during “risk period”  104 occurred during washout period  Therefore, of 300,000 patients, it seems that the risk of antihypertensive agents may have contributed to 39 more hip fractures.

Any thoughts from the audience?

Conclusions  This study supports that there is atleast to some degree an increased risk of hip fracture after patients initiate anti-hypertensive agents, most likely secondary to orthostatic hypotension.  No data to support that the risk actually outweighs the benefit of these medications  Use caution when beginning anti-hypertensive agents and warn your patients of side effects.  May be beneficial to actually check all of our patient’s blood pressures while they are standing.

References  Butt D, Muhammad M et al. The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly. JAMA Internal Medicine. 2012; 172(22):  Hemmelgarn BR, Chen G, Walker R, et al. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and Can J Cardiol. 2008;24(6):  Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):  Beckett N, Peters R, et al. Treatment of Hypertension in Patients 80 Years of Age and Older. New England Journal of Medicine. 2008; 358(18):  Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):  Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med. 1997;337(18):